{"id":"autologous-amniotic-fluid","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5315092","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amniotic fluid is rich in bioactive molecules including growth factors (FGF, HGF, TGF-β), anti-inflammatory cytokines, and undifferentiated stem cells. When administered autologously (from the patient's own pregnancy), these components are thought to stimulate tissue repair, modulate immune responses, and promote healing in damaged tissues. The exact mechanisms remain incompletely characterized and vary by clinical application.","oneSentence":"Autologous amniotic fluid contains growth factors, cytokines, and stem cells that promote tissue regeneration and reduce inflammation when administered therapeutically.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:19:49.834Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tissue regeneration and wound healing (specific indications not well-defined in published literature)"}]},"trialDetails":[{"nctId":"NCT04359472","phase":"NA","title":"The Collection and Application of Autologous Amniotic Fluid At Cesarean Delivery Closure.","status":"COMPLETED","sponsor":"Recibio, Inc.","startDate":"2020-10-01","conditions":"Pregnancy Related, Cesarean Wound Disruption, Cesarean Section; Infection","enrollment":20},{"nctId":"NCT06531356","phase":"PHASE4","title":"Efficiency of Autologous Amniotic Fluid Injection in the Healing of Cesarean Section Scar in High-Risk Population","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2024-02-16","conditions":"High Risk Pregnancy, Healing Surgical Wounds","enrollment":108},{"nctId":"NCT06200727","phase":"NA","title":"Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases","status":"UNKNOWN","sponsor":"Lei Du","startDate":"2023-01-01","conditions":"Platelet-rich Fibrin, Macular Holes, Pterygium","enrollment":170},{"nctId":"NCT02023372","phase":"NA","title":"Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine","status":"COMPLETED","sponsor":"NuTech Medical, Inc","startDate":"2013-12","conditions":"Intervertebral Disc Disease, Intervertebral Disc Degeneration, Spondylosis","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"autologous amniotic fluid","genericName":"autologous amniotic fluid","companyName":"Kasr El Aini Hospital","companyId":"kasr-el-aini-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Autologous amniotic fluid contains growth factors, cytokines, and stem cells that promote tissue regeneration and reduce inflammation when administered therapeutically. Used for Tissue regeneration and wound healing (specific indications not well-defined in published literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}